Study of Aripiprazole in Patients With Schizophrenia- Effects on Glucose Metabolism-

Exclusion Criteria

• •1. Patients who have been given aripiprazole after market launching
• •2. Patients who clearly experienced symptoms of polydipsia, including so-called PET-bottle syndrome (hyperglycemia caused when the supply of insulin, which promotes glucose metabolism, becomes insufficient due to continuous soft drink consumption) and water intoxication, within one year prior to giving informed consent
• •3. Patients taking drugs that affect glucose metabolism
• •4. Patients who take quetiapine fumarate (Seroquel) or olanzapine (Zyprexia) within a period from 12 weeks prior to commencement of study drug administration to immediately before commencement of study drug administration
• •5. Patients with the following complications Abnormal adrenal function, abnormal pituitary function, abnormal thyroid function, chronic pancreatitis, chronic hepatitis, alcoholic hepatopathy, non-alcoholic fatty liver, and liver cirrhosis
• •6. Female patients who are known to have given birth to a macrosomatic infant exceeding 4000 g in weight
• •7. Patients given antipsychotics at doses equivalent to 20 mg/day or more of haloperidol (or, in the case of multi-drug therapy, a combined equivalence of 20 mg/day or more of haloperidol) within a period from 12 weeks prior to commencement of study drug administration to immediately before commencement of study drug administration
• •8. Patients in a major state of excitation or stupor immediately before commencement of study drug administration
• •9. Patients who are forcibly hospitalized
• •10. Patients given any investigational new drugs within 12 weeks prior to commencement of study drug administration
• •11. Patients diagnosed as having a complication of serious hepatic, renal, cardiac, or haematopoietic disorder within 4 weeks prior to commencement of study drug administration, according to the criteria specified below.
• •Hepatic disorder: Total bilirubin ≥ 3.0 mg/dL, AST (GOT) and ALT (GPT) ≥2.5 times the upper limits of normal levels at the study site.
• •Renal disorder: Creatinine ≥ 2 mg/dL Heart: Congestive heart failure arrhythmias, and ischemic heart disease being treated by drug therapy Haematopoietic disorder, etc.: RBC \< 3,000,000, Hb \<10.0 g/dL, WBC \< 3,000, platelet counts \< 7,500
• •12. Pregnant or lactating women, women shown to be possibly pregnant by the pregnancy examination conducted immediately before commencement of study drug administration, and women who are hoping to become pregnant within one year after providing informed consent to participate in the study
• •13. Patients who meet any of the criteria for contraindication listed on the package insert of aripiprazole
• •14. Patients with a complication or history of neuroleptic malignant syndrome or a related condition
• •15. Patients suffering physical exhaustion associated with dehydration or malnutrition, etc.
• •16. Patients with a complication or history of paralytic ileus
• •17. Patients with a history of alcohol dependence or drug abuse
• •18. Patients with a history of suicide attempt, or patients who have a high possibility of committing self-injury or attempting suicide
• •19. Patients with a complication or history of convulsion disorders, such as epilepsy, or structural brain disorders
• •20. Patients considered in the judgment of the principal investigator or the attending investigator to be inappropriate for inclusion in the study for any other reason